A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine

Abstract

Abstract Background Vaccination is an important method for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission. There is currently a lack of real‐world clinical data regarding the safety and efficacy of coronavirus disease 2019 (COVID‐19) vaccines with respect to plaque psoriasis treatment involving tumor necrosis factor‐α (TNF‐α) and interleukin‐17A (IL‐17A) inhibitors. Methods We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID‐19 vaccine (either BBIBP‐CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF‐ α inhibitors or IL‐17A inhibitors) or acitretin. Routine blood tests were used to assess safety; the psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) were used to assess efficacy. Results After inactivated COVID‐19 vaccination, biologics retained considerable advantages in terms of improving skin lesions (measured by PASI) and quality of life (measured by DLQI), compared with conventional treatment (p 0.05). Conclusions Inactivated SARS‐CoV‐2 vaccines do not have significant impacts on the safety and efficacy of biologics (TNF‐α inhibitors or IL‐17A inhibitors) in patients with moderate to severe plaque psoriasis.

Keywords

• biologics
• inactivated SARS‐CoV‐2 vaccine
• psoriasis